C2N Diagnostics Announces Anthem BCBS As Nation’s First To Cover PrecivityAD2 Blood Test For Alzheimer’s Disease Biomarkers

C2N Diagnostics, LLC (C2N) announced that, beginning October 1, 2026, eligible Anthem Blue Cross and Blue Shield members will be the first in the United States to receive insurance coverage for the PrecivityAD2 blood test for Alzheimer’s disease. The coverage is under a new medical policy. The test helps health care professionals evaluate adults experiencing cognitive decline or other symptoms associated with Alzheimer's disease. The PrecivityAD2 test is available in all 50 states and the District of Columbia and can be ordered by a health care professional.

The PrecivityAD2 blood test estimates the likelihood of amyloid plaques in . . .